Hospira said it has been working with Food and Drug Administration regulators on its quality issues, which have negatively impacted the company’s sales in the last year.
According to the report, Hospira reported a stronger-than-expected 6 percent profit increase in the first quarter. Net income rose to $149.9 million, or 88 cents a share, from $141.7 million, or 84 cents a share, a year earlier.
Read the Chicago Tribune report on Hospira.
Related Articles on Drug Shortages:
American Society of Anesthesiologists Conducts Survey on Drug Shortages
South Dakota Hospitals Search for Ways to Weather Drug Shortage
Drug Shortages Cost Providers $200M Annually, Endanger Patient Safety
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.